Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Takeaways From Amarin's Earnings

TheMotleyFool

0 0

Before the opening bell on Wednesday, Amarin (NASDAQ: AMRN) reported its second-quarter earnings, with the biopharma easily beating the consensus for both its top and bottom lines for the three-month period. In fact, the company reported a record-setting revenue haul of $100.8 million in the second quarter, fueled by surging sales of the prescription omega-3 treatment Vascepa.

While stronger-than-expected earnings are always a positive, Amarin's Q2 report arguably gave investors a lot more to chew on than just financial facts and figures. Here are three key takeaways from the biotech's upbeat earnings release.

Image source: Getty Images.

Quelle Fool.com

Like: 0

AMRN

Share